EPO board: no legal basis for adapting description text prior to grant

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO board: no legal basis for adapting description text prior to grant

Sponsored by

inspicos-400px recrop.jpg
Patent agreement.jpg

An EPO board of appeal decision has challenged the office’s standing in requiring applicants to adapt the description text of patent applications to be in accordance with amended claims, says Edward Farrington of Inspicos

For many years, the EPO has required applicants to align the description text of a patent application with amended claims before an application can proceed to grant (Guidelines for Examination in the European Patent Office, Part H, Chapter V, 2.7).

Applicants can be requested to delete examples or embodiments that are no longer within the scope of the claims, general statements, or "spirit of the invention" or claim-like clauses. EPO examiners typically relied on the second sentence of Article 84 of the European Patent Convention (EPC) as the legal basis for this requirement, which states “[the claims] shall be clear and concise and be supported by the description.”

However, in a newly published decision from an EPO board of appeal, T 56/21, the applicant (F. Hoffmann-La Roche AG) challenged the legal basis for the EPO’s requirements. During examination of the application, the EPO examiner required the claim-like clauses in the application text to be deleted. Hoffmann-La Roche refused, the application was rejected, and an appeal was filed.

The board in T 56/21 considered Article 84 and Article 69 of the EPC, and how the relationship between the patent claims and the description text is governed. Among other things, the board concluded that these articles of the EPC should be kept separate – the assessment of clarity of a patent application was a task for the EPO’s examining division, while the “protection conferred by a patent” is a matter for consideration by national courts in infringement proceedings. Furthermore, Article 84 of the EPC sets out requirements to be met by the claims and not by the description. Accordingly, if a claim lacked clarity, the board stated that this should be remedied by amending the claim itself, and not by considering the description text.

It is hoped that this decision, issued on October 4 2024, becomes established case law, and that the Guidelines for Examination in the European Patent Office are updated to reflect decision T 56/21. At least, the decision appears to provide justification for applicants who may not wish to align the description text with claims intended for grant.

more from across site and SHARED ros bottom lb

More from across our site

AG Barr acquires drinks makers Fentimans and Frobishers, in deals worth more than £50m in total
Tarun Khurana at Khurana & Khurana says corporates must take the lead if patent filing activity is to truly translate into innovation
Michael Moore, head of legal at Glean AI, discusses how in-house IP teams can use AI while protecting enforceability
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
After Matthew McConaughey registered trademarks to protect his voice and likeness against AI use, lawyers at Skadden explore the options available for celebrities keen to protect their image
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Arun Hill at Clarivate assesses the Top 100 Global Innovators 2026 list, including why AI has assumed a strategic importance for innovation
Gift this article